Skip to main content
OpenTrials
Completed

NCT Number: NCT04983654

Functional and Mechanistic Characterization of Limb Ulcers in Patients With Sickle Cell Disease

Sickle Cell Disease is the most frequent genetic disease in the world (representing one birth over 1900, in France). The polymerization of the abnormal hemoglobin (i.e., HbS) when deoxygenated is at the origin of a mechanical distortion of red blood cells (RBC) into a crescent-like shape. Sickled RBCs are very fragile and rigid, which lead patients to have severe anemia and to develop frequent and repeated painful vaso-occlusive crises. Furthermore, the repetition of sickling-unsickling cycles causes irreversible damages to the RBCs, which shorten their half-life. Accumulation of free hemoglobin and heme in the plasma is involved in blood vessels lesions in both the macro- and micro- circulation.

The resulting vascular dysfunction could explain why limb ulcers are 10 fold more frequent in patients with sickle cell disease compared to the general population and may happen at a younger age. Limb ulcers induce significant morbidity (delay of healing between 9 and 26 weeks in the french cohort), and are associated to significant pain (needing opioid pain-killer) and increase the risk of infection. Cost of care is also increased. Moreover, ulcers induce missed school and work days.

Data on cutaneous microcirculation and ulcers physiopathology in patients with sickle cell disease are scarce. We want to realise a microcirculatory and neurological functional study of patients with with and without ulcers and a characterization of biomarkers present in the blood or in the wound fluid which can participate to ulcers physiopathology.

To ensure healing, adapted therapeutics are essential. Several strategies are proposed such as: lifestyle measures (venous compression, lower limb elevation, rest), dressings, hyperbaric oxygenotherapy (also used in diabetic ulcers). The project is devoted to study the mechanisms involved in leg ulcers and the effects of therapeutical/behavioral strategies.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sickle Cell Disease (homozygous SS or Sb0)
  • Age ≥ 18 years old
  • Consent patients
  • Social regimen

Exclusion criteria

  • tutela or curatella
  • Vaso occlusive crisis < 1 month

Treatment and study plan

patients with limb ulcers

Diagnostic Test

For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:

  • Microvascular analysis (laser doppler, TcPO2),
  • Neurological analysis ( sensitivity testing with thermal and mechanical test),
  • Analysis of physical characteristics of red blood cells and inflammatory marks,
  • Analysis of cytokine and metalloproteases in the wound fluid,
  • Assessment of healing according usual treatment

For patients without limb ulcers

Diagnostic Test

For patients without limb ulcers : at inclusion visit only

  • Microvascular analysis (laser doppler, TcPO2),
  • Neurological analysis (sensitivity testing with thermal and mechanical test),
  • Analysis of physical characteristics of red blood cells and inflammatory marks

Primary outcomes

  1. Alteration of cutaneous microvascular function and peripheral sensorial neurological function in patients with limb ulcers

    Time frame: Day 1

    Cutaneous microvascular function is assessed with :

    • laser Doppler Including measurement of blood pressure before and after testing, heart rate before and after testing, cutaneous temperature, values of laser Doppler before and after vasodilatation with acetylcholine, deionized water, local heating (42°C)
    • TcPO2 on the first intermetatarsal space and bordering ulcer Peripheral sensorial neurological function is assessed with Von Frey monofilament, hot (50°C)/cold (4°C) test, pic-touch test and pallesthesia.

Secondary outcomes

  1. Modification of hemorheological red blood cells characteristics between patients with and without ulcers

    Time frame: Day 1

    Analysis of hemorheological characteristics in the 2 arms after blood test with blood viscosity and RBC rheological measurements (deformability/aggregation)

  2. Analysis of the composition of the wound fluid

    Time frame: Day 1

    Analysis of metalloproteases (MMP-8 and MMP-9) and inflammatory markers (TNF-alpha, Il-6, Il1-beta, VCAM 1, P-selectin) in the wound fluid

  3. Compare pro inflammatory markers in the blood between patients with and without ulcers

    Time frame: At initial visit

    Analysis of inflammatory markers in the blood and comparison between the 2 arms

  4. Assessment of healing

    Time frame: through study completion, an average of 6 months

    Delay of granulation tissue appearance, delay of healing according treatment used

  5. Compare microcirculation, pro inflammatory marker in the wound fluid and in the blood and hemorheological characteristics after usual treatment to obtain healing

    Time frame: through study completion, an average of 6 months

    Compare results (previously described) in the group of patients with ulcers, between initial and second visit

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: DrepanO2

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jul 30, 2021
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.